TY - GEN 
A1 - Esteban Fernández, Alberto
AU - Díez Villanueva, Pablo
AU - Vicent, Lourdes
AU - Bover Freire, Ramón
AU - Gómez Bueno, Manuel
AU - Juan Bagudá, Javier de
AU - Iniesta, Ángel Manuel
AU - García Aguado, Marcos
AU - Martínez Sellés Oliveria Soares, Manuel
T1 - Sacubitrilo/valsartán es útil y seguro en ancianos con insuficiencia cardiaca con fracción de eyección reducida. Datos de una cohorte en vida real

Y1 - 2020
UR - http://hdl.handle.net/11268/8838
AB - Background
HF elderly patients are underrepresented in Sacubitril/Valsartan HF trials, and the effect of S/V in real-life patients with advanced age is unknown. The aim of this study was to evaluate the use and safety of S/V in a real-word cohort of elderly patients.

Methods
We performed a prospective registry of patients who started S/V in clinical practice. We compared baseline characteristics, adverse events during follow-up and causes of S/V withdrawal according to age.

Results
A total of 427 patients started treatment with S/V: 222 (52.0%)<70 years old, 140 (32.8%) between 70 and 79 and 65 (15.2%)≥80. During a mean follow-up of 7.0±0.1months S/V was well tolerated, with no age-related differences in adverse events (26.8%, 25.9%, 23.1% respectively; p=0.83). Symptomatic hypotension tended to be more frequent in the elderly (19.8%, 25.6%, 33.3% respectively; p=0.17). The withdrawal of S/V was more frequent in younger patients (14.4%, 10.0%, 4.6% respectively; p=0.05) and related to poor prognosis (HR 13.51, 95% CI 3.22–56.13, p<0.001).

Conclusions
Sacubitril/Valsartan is useful and safe in elderly people with HF-rEF in real-life clinical practice, and withdrawal is associated to poor prognosis. The doses achieved are lower in elderly people.

KW - Geriatría
KW - Enfermos cardíacos
KW - Medicamentos cardiovasculares
KW - Gerontología
KW - Enfermedad cardiovascular
KW - Medicamento
LA - eng
ER -